Join our daily newsletter At The Bell to receive exclusive market insights
- Research data from Botanix Pharmaceuticals’ (BOT) antimicrobial program has been published in Communications Biology, Nature Research’s peer-reviewed journal
- The research data, owned by Botanix and covered by several patent applications, demonstrates the antimicrobial ability of cannabidiol against Gram-negative bacteria
- This group of bacteria is responsible for gonorrhoea, meningitis and legionnaires disease
- Testing by Botanix has also shown the potential of synthetic analogs of cannabinoids as a potential new class of antimicrobials
- The company has recently completed its Phase 2a BTX 1801 synthetic antimicrobial study and maintains it’s on track to release data later this quarter
- Shares in BOT have been trading 7.4 per cent higher at 14.5 cents
Research data from Botanix Pharmaceuticals’ (BOT) antimicrobial program has been published in Communications Biology, Nature Research’s peer-reviewed journal.
The article entitled “The antimicrobial potential of cannabidiol” is based research data which is owned by Botanix and covered by several patent applications.
The research demonstrates the antimicrobial ability of cannabidiol against Gram-negative bacteria, responsible for gonorrhoea, meningitis and legionnaires disease.
Importantly, the article highlights that cannabidiol can selectively kill certain Gram-negative bacteria including Neisseria gonorrhoea, flagged by both the World Health Organization and Centers for Disease Control and Prevention as a key pathogen.
Testing by Botanix has also shown the potential of synthetic anologs of cannabinoids as a potential new class of antimicrobials, an advancement which would have global significance in an era of antimicrobial resistance.
“The published data clearly establishes Botanix as the world leader in characterising and exploiting the pharmaceutical potential of synthetic cannabinoids as antimicrobials – and vast potential for the development of novel and effective treatments,” President and Executive Chairman Vince Ippolito said.
Botanix recently completed its Phase 2a BTX 1801 synthetic antimicrobial study and today revealed it’s on track to release the data later this quarter.
The study is evaluating the safety and tolerability of two formulations of BTX 1801 nasal ointment in decolonising staphylococcus aureus (Staph) and methicillin-resistant Staphylococcus aureus (MRSA) from the nasal cavity.
These bacteria can cause life-threatening infections following surgery, however the overuse of Bactroban, otherwise known as mupirocin, has lead to the development of bacterial resistance.
Shares in BOT have been trading 7.4 per cent higher following today’s publication announcement, trading at 14.5 cents at 10:12 am AEDT.
